CEO Christopher Kirk was paid $927,300 in fiscal year 2024 (SEC filing 0001645666-25-000020 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$927,300 Christopher Kirk total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Kirk | $600,000 | $0 | $0 | $0 | $313,500 | $0 | $13,800 | $927,300 |
| Chief Executive Officer | ||||||||
| Marc Belsky | 462,000 | 0 | 0 | 261,835 | 177,408 | 0 | 13,800 | 915,043 |
| Chief Financial Officer | ||||||||
| Mark Schiller | 451,000 | 0 | 0 | 230,393 | 173,185 | 0 | 13,800 | 868,378 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Christopher Kirk | $927,300 | $2,602,155 | — | ↓ −1,674,855 |
| Marc Belsky | 915,043 | 2,006,319 | — | ↓ −1,091,276 |
| Mark Schiller | 868,378 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Kezar Life Sciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KZR reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses KZR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KZR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Kirk | Option | 542 | 22.8 | — |
| Mark Schiller | PSU | 1,500 | — | 10,080 |
| Mark Schiller | Option | 3,520 | 22.8 | — |
| Mark Schiller | Option | 230 | 22.8 | — |
| Marc Belsky | Option | 22,739 | 9.3 | — |
| Christopher Kirk | Option | 4,604 | 22.8 | — |
| Christopher Kirk | Option | 9,896 | 22.8 | — |
| Christopher Kirk | Option | 63,803 | 8.4 | — |
| Marc Belsky | Option | 458 | 22.8 | — |
| Mark Schiller | Option | 12,000 | 6.3 | — |
| Marc Belsky | Option | 3,791 | 22.8 | — |
| Marc Belsky | Option | 10,156 | 22.8 | — |
| Marc Belsky | Option | 12,000 | 6.3 | — |
| Mark Schiller | Option | 8,593 | 22.8 | — |
| Mark Schiller | Option | 19,271 | 9.3 | — |
Compensation of our named executive officers is designed to enable the Company to attract and retain talented and experienced executives to lead us successfully in a competitive environment. We believe that our compensation policies and decisions are consistent with current market practices.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Graham CooperIndependent · Audit Committee (Chair) · Compensation Committee | $90,000 | — | $24,375 | — | — | $114,375 |
| Elizabeth GarnerIndependent · Audit Committee | 57,500 | — | 24,375 | — | — | 81,875 |
| Franklin BergerIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) | 55,500 | — | 24,375 | — | — | 79,875 |
| Micki KlearmanIndependent · Nominating and Corporate Governance Committee | 54,000 | — | 24,375 | — | — | 78,375 |
| Courtney WallaceIndependent · Compensation Committee · Nominating and Corporate Governance Committee | 49,000 | — | 24,375 | — | — | 73,375 |
| John FowlerIndependent | 57,037 | — | 324,889 | — | — | 57,037 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 4,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $363,037 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $363,037 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kezar Life Sciences | 2024 | Christopher Kirk | $600,000 | $0 | $0 | $313,500 | $927,300 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Kirk | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Executive Compensation”. As printed: 927,300. Filing ↗machine: span 286147–286154 |
| 2 | Section 01, Marc Belsky | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Executive Compensation”. As printed: 915,043. Filing ↗machine: span 293845–293852 |
| 3 | Section 01, Mark Schiller | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Executive Compensation”. As printed: 868,378. Filing ↗machine: span 301646–301653 |
| 4 | Section 08, Graham Cooper | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 114,375. Filing ↗machine: span 447635–447946 |
| 5 | Section 08, Elizabeth Garner | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 81,875. Filing ↗machine: span 450843–451153 |
| 6 | Section 08, Franklin Berger | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 79,875. Filing ↗machine: span 446051–446387 |
| 7 | Section 08, Micki Klearman | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 78,375. Filing ↗machine: span 453930–454240 |
| 8 | Section 08, Courtney Wallace | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 73,375. Filing ↗machine: span 455465–455775 |
| 9 | Section 08, John Fowler | DEF 14A | 2025-04-25 | 0001645666-25-000020 | Section “Director Compensation”. As printed: 57,037. Filing ↗ |
| 10 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 11 | Section 09b board cost (computed) | Computed | — | — | Cash 363,037 + equity 0 + all other 0 = 363,037, summed across the director compensation table rows.machine: formula: Σ = 363,037 |
| 12 | Kezar Life Sciences (subject), Section 10b CEO total | DEF 14A | 2025-04-25 | 0001645666-25-000020 | CEO total compensation as printed in Kezar Life Sciences's own proxy. As printed: 927,300. Filing ↗machine: span 286147–286154 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat